-22% Off

Retatrutide 20mg

Original price was: $225.00.Current price is: $175.00.

Retatrutide is a highly promising investigational drug for obesity and metabolic disease due to its triple receptor agonist action. It has shown very large weight loss (20‑25%+) in trials lasting ~48 weeks at higher doses (8‑12 mg).
It remains experimental — human clinical trial data beyond ~1 year, at doses above 12 mg weekly, or in diverse populations is limited.

Description

Retatrutide 20mg (also known as LY3437943) is an investigational triple‐agonist peptide drug in development by Eli Lilly.
It targets three hormone receptors:
1. GLP‑1 (Glucagon-Like Peptide‑1)
2. GIP (Glucose‑Dependent Insulinotropic Polypeptide)
3. Glucagon receptor
The rationale is that combining these three actions may provide superior weight loss, metabolic improvements, and energy expenditure increases compared to drugs that target only one or two of these pathways.

Here are the key findings from phase 2 (and other) trials to date:

Dose	Duration	Average Weight Loss vs Placebo	Other Effects / Notes
1 mg weekly	24 weeks	~ −7.2% body weight	Mild to moderate GI side effects; start dose matters for tolerability.
4 mg	24 weeks	~ −12.9%	Improved metabolic markers (glucose, lipids)
8 mg	24 weeks	~ −17.3%	More pronounced effects; side effects increase but generally manageable with dose escalation.
12 mg	24 weeks	~ −17.5%	At 48 weeks: ~ −24.2% body weight for highest doses.

In one substudy of participants with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD/NAFLD), large reductions in liver fat % were observed (up to ~80‑82% in 8 mg or 12 mg dose groups over 24 weeks).
Improvements also noted in cardiometabolic markers: aspects like HbA1c (for glucose control), lipids, blood pressure.
The safety profile in trials has been similar to that observed for GLP‑1 / GIP‑GLP‑1 agonists. The most common side effects are gastrointestinal (GI: nausea, diarrhea, vomiting).

Retatrutide 20mg is administered via subcutaneous injection once weekly.
Approximate half‑life is ~ 6 days which supports once‑weekly dosing.
Dose‑escalation at the start of therapy improves tolerability (e.g. starting low, then increasing doses).

Some vendors list “Retatrutide 20 mg (Research & Development only)” pens or kits. These are not approved for human therapeutic use. Such products are outside standard clinical trial channels and may be unverified, variable in quality, etc. Regulatory bodies have issued warnings about unapproved, counterfeit, or mislabelled weight‑loss drugs marketed online.
The clinical trials published so far have tested up to 12 mg weekly doses in humans. There is no published, peer‑reviewed clinical data showing safety or efficacy of 20 mg (or 40 mg) doses in registered trials.

Substantial weight loss: as high as ~ 24.2% body weight over ~ 48 weeks in highest tested doses.
Liver fat reduction: potential to improve or resolve steatosis in many patients.
Metabolic improvements: better glucose control, lipids, blood pressure